CSIMarket
 
Palisade Bio Inc   (PALI)
 

Between many corporations, the Palisade Bio Inc disclosed as well the second quarter of 2022 numbers

company announced second quarter of 2022 operating shortfall of $-3.572 million


Published Aug 17 2022
CSIMarket Team / CSIMarket.com


Red_pill_wikipedia_By_FML_(Own_work)_[CC-BY-SA-2.5_(http_creativecommons.org_licenses_by-sa_2.5)]_via_Wikimedia_Commons While the earnings season of the April to June 30 2022 goes on, many corporations have declared the numbers. In the thick of it, have been many constituents of the Biotechnology & Pharmaceuticals industry. And today, Palisade Bio Inc disclosed operating shortfall of $-3.572 million, for the most recent fiscal period.

It is eye-catching that, the emerging growth company did operate more economically, then in the comparable period a prior year. Coming from operating shortfall of $-32.858 million.


Now, there was also some alleviation on the deficit. as the deficit has been reduced from the time frame, a year prior. It is a essential observation in the financial second quarter of 2022. Shortfall was $-2.344 million, while in the second quarter of 2021 $-31.746 million.


Palisade Bio Inc is expected to report next financial recent numbers on May 12, 2023.



Palisade Bio Inc's Net Income Growth

Palisade Bio Inc's Dividend Growth



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com